RegCell secures funding and completes US headquarters transition

RegCell, a Japanese-founded biotechnology company, has announced the closing of an oversubscribed seed round and its transition to a USA-based company, based in Emeryville, California.

Currently based in Osaka, RegCell’s proprietary best-in-class platform allows the generation of epigenetically reprogrammed antigen-specific regulatory T-cells (Tregs) that are stable in vivo and maintain a high degree of functionality (S/F-Epigen-Tregs) to restore immune tolerance and ultimately reverse autoimmune disorders as well as the limitations with transplantation.

The $8.5 million seed financing was co-led by the University of Tokyo Edge Capital Partners (UTEC) and Fast Track Initiative (FTI), with participation from Celadon Partners, Mitsubishi UFJ Capital, Osaka University Venture Capital (OUVC), and Kyoto University Innovation Capital (Kyoto i-Cap).